F. Primi

Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study

D. Giannarelli, M. Mazzotta, M. Schirripa, 2022, International Immunopharmacology.

Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis

T. Ranalli, R. Santoro, G. Pessina, 2022, Cureus.

Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients

C. Fiore, D. Giannarelli, M. Mazzotta, 2022, Scientific reports.

Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study

D. Giannarelli, M. Mazzotta, M. Schirripa, 2021, ESMO Open.

Solitary Fibrous Tumor/Hemangiopericytoma of the Penis: Report of the First Case

D. Castellani, G. Sebastiani, F. Primi, 2015, Urologia.

Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study

D. Giannarelli, G. Pessina, M. Schirripa, 2023, Current oncology.

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

G. Pessina, D. Giannarelli, M. Mazzotta, 2022, Annals of Oncology.

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study

G. Pessina, D. Giannarelli, M. Mazzotta, 2021, Annals of Oncology.

Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?

G. Tortora, S. Buti, F. Massari, 2022, AntiCancer Research.

Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study

D. Giannarelli, M. Schirripa, E. Ruggeri, 2023, Cancers.

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.

D. Giannarelli, M. Schirripa, E. Ruggeri, 2023, Cancer immunology, immunotherapy : CII.

[Calcitonin gene-related peptide in diabetes mellitus type 2: a possible etiopathogenetic role].

G. Minniti, F. Primi, C. Parlapiano, 1995, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques.

Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).

N. Segata, A. Gasbarrini, G. Tortora, 2022, Journal of Clinical Oncology.

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.

P. Marchetti, D. Santini, E. Cortesi, 2016 .

Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.

M. Mazzotta, M. Schirripa, E. Ruggeri, 2022, Cancer diagnosis & prognosis.

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.

G. Tortora, S. Buti, C. Ciccarese, 2024, European urology.